The latest price of imported dasatinib

Dasatinib (Dasatinib) is an oral multi-target tyrosine kinase inhibitor developed by Bristol-Myers Squibb in the United States. The drug is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). It is suitable for patients who have failed or are intolerant to imatinib treatment. As a second-generation BCR-ABL inhibitor, dasatinib has higher target selectivity than traditional TKIs and can inhibit a variety of mutant BCR-ABL. It can also act on Src family kinases, c-KIT and PDGFR, thus showing significant therapeutic potential in drug-resistant patients.

In recent years, with the popularization of the concept of precision treatment, dasatinib has gradually become one of the core drugs for CML and Ph+ ALL. Domestically, the drug has been approved by the State Food and Drug Administration and included in the medical insurance catalog. Medical insurance reimbursement is mainly targeted at patients who meet specific stages and mutation types, which greatly reduces the burden of medication. At present, the common specifications in the market are 50mg×60 tablets and 20mg×60 tablets, and the price after medical insurance is about 10,000 yuan. It is worth noting that the patient's final out-of-pocket amount will vary depending on regional policies and individual insurance categories.

In overseas markets, the price of the original drug of dasatinib is significantly higher than that in China. Taking the US market as an example, the average monthly cost of Sprycel often exceeds US$10,000. Therefore, many countries around the world have promoted the production and import of generic versions. Generic dasatinib drugs produced by pharmaceutical companies in India, Bangladesh and other countries are basically the same as the original drugs in terms of drug ingredients, bioequivalence and clinical efficacy, but the price is as low as a few hundred yuan. Such generic drugs are widely used for long-term management of CML in non-profit medical institutions in some countries, providing economically feasible treatment alternatives for low- and middle-income patients.

Reference materials:https://go.drugbank.com/drugs/DB01254